Abeona Therapeutics Inc vs EOG Resources Inc — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $424.33M), while EOG Resources Inc trades at $143.45 (market cap $74.60B). The key difference: EOG Resources Inc is far larger — about 175.8× Abeona Therapeutics Inc's market cap, and EOG Resources Inc pays a 2.87% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EOG | |
|---|---|---|
Market Cap | $424.33M | $74.60B |
Sector | Health | Energy |
52-Week High | $7.45 | $149.89 |
52-Week Low | $4.17 | $101.78 |
Enterprise Value | $279.23M | $77.94B |
Dividend Yield | — | 2.87% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
EOG Resources trades at $134.74, down 1.07% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $5.07, beating estimates, with revenue growth driven by higher oil prices and production. Valuation metrics remain attractive with P/E of 10.49 and EV/EBITDA of 5.32, while maintaining robust profitability with 25.81% net margin and 22.51% ROE.
EOG presents a compelling value opportunity with strong earnings momentum and shareholder returns through dividends. However, negative cash flow trends and energy price volatility pose near-term risks. Analyst consensus remains bullish with $162.11 price target, representing 20% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →